Compass Pathways' New Data Boosts Market Confidence
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: stocktwits
- Durability Data Boosts Confidence: Evercore noted that the 26-week data for COMP006 closely mirrors earlier COMP005 results, alleviating concerns about treatment durability and enhancing market confidence in COMP360, which is expected to receive FDA approval by the first half of 2027.
- Significant Clinical Trial Results: COMP360 demonstrated a 39% symptom reduction in patients by week six in the second Phase 3 trial, with effects lasting at least six months, significantly outperforming the 25% response rate seen in COMP005, indicating strong efficacy and good tolerability of the treatment.
- Analysts Optimistic About Future: Stifel raised its price target to $21, implying a 50% upside, believing that the durability data supports COMP360's clinical edge and boosts confidence in a potential 2027 launch, with peak revenue expectations lifted to $1.5 billion.
- Retail Sentiment Extremely Bullish: On Stocktwits, retail sentiment for CMPS surged to 83/100, its highest in a month, with message volume jumping 200%, reflecting investor optimism about COMP360's potential in the treatment-resistant depression market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CMPS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CMPS
Wall Street analysts forecast CMPS stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 12.990
Low
8.00
Averages
18.43
High
40.00
Current: 12.990
Low
8.00
Averages
18.43
High
40.00
About CMPS
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Compass Pathways' New Data Boosts Market Confidence
- Durability Data Boosts Confidence: Evercore noted that the 26-week data for COMP006 closely mirrors earlier COMP005 results, alleviating concerns about treatment durability and enhancing market confidence in COMP360, which is expected to receive FDA approval by the first half of 2027.
- Significant Clinical Trial Results: COMP360 demonstrated a 39% symptom reduction in patients by week six in the second Phase 3 trial, with effects lasting at least six months, significantly outperforming the 25% response rate seen in COMP005, indicating strong efficacy and good tolerability of the treatment.
- Analysts Optimistic About Future: Stifel raised its price target to $21, implying a 50% upside, believing that the durability data supports COMP360's clinical edge and boosts confidence in a potential 2027 launch, with peak revenue expectations lifted to $1.5 billion.
- Retail Sentiment Extremely Bullish: On Stocktwits, retail sentiment for CMPS surged to 83/100, its highest in a month, with message volume jumping 200%, reflecting investor optimism about COMP360's potential in the treatment-resistant depression market.
See More
US Launches Fresh Strikes on Iran Amid Rising Tensions
- Military Escalation: The U.S. launched fresh airstrikes on Iran in response to Tehran's attacks on three commercial ships in the Strait of Hormuz, a move that not only escalates regional tensions but also threatens global oil prices and shipping safety.
- Market Reaction: Despite the Dow Jones Industrial Average dropping over 570 points to close down 1.09%, the Nasdaq Composite rose 0.2% due to gains in semiconductor stocks, reflecting the market's complex response to the escalating situation.
- Inflation Concerns Intensify: The minutes from the Federal Reserve's June meeting revealed growing concerns among policymakers about inflation pressures, with some arguing for a potential rate hike, which could influence future monetary policy directions.
- Oil Price Volatility: Amid fears of renewed strikes on Iran, Brent crude futures rose nearly 1% to around $78.77 per barrel, indicating the market's sensitivity to geopolitical risks that could lead to further fluctuations in oil prices.
See More
Evercore ISI Upgrades Compass Pathways to Outperform with Price Target Raised to $21
- Rating Upgrade: Evercore ISI upgraded Compass Pathways from Inline to Outperform and raised its price target from $8 to $21, reflecting increased confidence in the long-term efficacy of its psychedelic therapy COMP360.
- Clinical Trial Results: The 26-week results from the 581-patient Phase 3 COMP006 trial demonstrated rapid onset and durable clinical effects of COMP360, further solidifying its potential in treating treatment-resistant depression.
- FDA Expectations: Analysts anticipate FDA approval for COMP360 in H1 2027, with initial commercial rollout expected to be slow, yet this sets a foundation for long-term growth in the mental health sector.
- Infrastructure Development: As the necessary infrastructure is built, Compass Pathways plans to gradually launch COMP360 over the next few quarters, facing initial challenges but maintaining an optimistic long-term outlook.
See More
Positive COMP360 Data Boosts Stock Price
- Positive Clinical Data: Compass Pathways PLC (CMPS) announced that its second late-stage trial of COMP360 showed significant symptom relief for patients with treatment-resistant depression, with effects lasting at least six months, potentially paving the way for a future FDA application.
- Analyst Ratings Remain Optimistic: Analysts from Stifel, Oppenheimer, and Wolfe Research maintained positive ratings on CMPS, with Oppenheimer setting a price target of $20, indicating a potential upside of about 54%, reflecting a strong belief in the long-term market opportunity for COMP360 despite the current stock price not fully capturing its potential.
- Market Reaction Volatility: CMPS shares experienced a trading session with swings of up to 10%, ultimately closing up 1% at $12.99, indicating that investors were taking profits after the positive data release; analysts suggest this volatility may be an overreaction to good news, with expectations of a rebound in momentum.
- Retail Investor Sentiment Bullish: According to a Stocktwits poll, retail sentiment around CMPS remains in the 'bullish' zone, with 25% of approximately 750 respondents expressing confidence in the stock's prospects over the next five years, further supporting its market outlook.
See More
Compass Pathways' COMP360 Shows Strong Phase 3 Data for TRD
- Clinical Trial Results: Among patients receiving a 25 mg dose, 39% achieved a clinically meaningful reduction in depression symptoms by Week 6 and maintained these benefits through at least Week 26, significantly improving on the 25% response rate seen in the COMP005 trial, indicating COMP360's potential in treating treatment-resistant depression (TRD).
- Positive Stock Reaction: Shares of Compass Pathways jumped over 10% in pre-market trading on Tuesday, and if current levels hold after the opening bell, it would mark the biggest single-day gains in nearly two months, reflecting strong market confidence in the new therapy.
- FDA Application Progress: The company has begun a rolling New Drug Application submission to the U.S. FDA, with the final filing expected in Q4 2026, and if approved, COMP360 is anticipated to launch in the first half of 2027, further advancing its late-stage PTSD program.
- Optimistic Market Sentiment: Retail sentiment surrounding CMPS on Stocktwits remained in the 'bullish' zone, with message volumes surging 225% over a 24-hour period, as some users predict the stock could climb to $20 before the closing bell, representing a potential 35% increase.
See More
Compass Pathways Releases New Data on COMP360 for Treatment-Resistant Depression
- Clinical Trial Progress: Compass Pathways confirmed the potential of COMP360 against treatment-resistant depression in its 581-patient Phase 3 COMP006 trial, with 26-week results demonstrating rapid onset and durable clinical effects, boosting market confidence in its therapy.
- Efficacy Data Highlights: In the COMP006 trial, 39% of patients receiving two doses of 25 mg COMP360 achieved at least a 25% reduction in MADRS scores by Week 6, compared to only 25% in the COMP005 trial, indicating the clinical benefits of dose escalation.
- Safety Profile Remains Strong: The experimental therapy showed no new safety events and continued to indicate a well-tolerated safety profile, enhancing investor confidence in its future market performance.
- FDA Application Progress: Compass Pathways is conducting a rolling submission for a new drug application expected to conclude in Q4 2024, with COMP360 anticipated to launch in H1 2027, subject to FDA approval, further driving company growth.
See More
Compass Pathways' New Data Boosts Market Confidence
- Durability Data Boosts Confidence: Evercore noted that the 26-week data for COMP006 closely mirrors earlier COMP005 results, alleviating concerns about treatment durability and enhancing market confidence in COMP360, which is expected to receive FDA approval by the first half of 2027.
- Significant Clinical Trial Results: COMP360 demonstrated a 39% symptom reduction in patients by week six in the second Phase 3 trial, with effects lasting at least six months, significantly outperforming the 25% response rate seen in COMP005, indicating strong efficacy and good tolerability of the treatment.
- Analysts Optimistic About Future: Stifel raised its price target to $21, implying a 50% upside, believing that the durability data supports COMP360's clinical edge and boosts confidence in a potential 2027 launch, with peak revenue expectations lifted to $1.5 billion.
- Retail Sentiment Extremely Bullish: On Stocktwits, retail sentiment for CMPS surged to 83/100, its highest in a month, with message volume jumping 200%, reflecting investor optimism about COMP360's potential in the treatment-resistant depression market.
See More
US Launches Fresh Strikes on Iran Amid Rising Tensions
- Military Escalation: The U.S. launched fresh airstrikes on Iran in response to Tehran's attacks on three commercial ships in the Strait of Hormuz, a move that not only escalates regional tensions but also threatens global oil prices and shipping safety.
- Market Reaction: Despite the Dow Jones Industrial Average dropping over 570 points to close down 1.09%, the Nasdaq Composite rose 0.2% due to gains in semiconductor stocks, reflecting the market's complex response to the escalating situation.
- Inflation Concerns Intensify: The minutes from the Federal Reserve's June meeting revealed growing concerns among policymakers about inflation pressures, with some arguing for a potential rate hike, which could influence future monetary policy directions.
- Oil Price Volatility: Amid fears of renewed strikes on Iran, Brent crude futures rose nearly 1% to around $78.77 per barrel, indicating the market's sensitivity to geopolitical risks that could lead to further fluctuations in oil prices.
See More
Evercore ISI Upgrades Compass Pathways to Outperform with Price Target Raised to $21
- Rating Upgrade: Evercore ISI upgraded Compass Pathways from Inline to Outperform and raised its price target from $8 to $21, reflecting increased confidence in the long-term efficacy of its psychedelic therapy COMP360.
- Clinical Trial Results: The 26-week results from the 581-patient Phase 3 COMP006 trial demonstrated rapid onset and durable clinical effects of COMP360, further solidifying its potential in treating treatment-resistant depression.
- FDA Expectations: Analysts anticipate FDA approval for COMP360 in H1 2027, with initial commercial rollout expected to be slow, yet this sets a foundation for long-term growth in the mental health sector.
- Infrastructure Development: As the necessary infrastructure is built, Compass Pathways plans to gradually launch COMP360 over the next few quarters, facing initial challenges but maintaining an optimistic long-term outlook.
See More
Positive COMP360 Data Boosts Stock Price
- Positive Clinical Data: Compass Pathways PLC (CMPS) announced that its second late-stage trial of COMP360 showed significant symptom relief for patients with treatment-resistant depression, with effects lasting at least six months, potentially paving the way for a future FDA application.
- Analyst Ratings Remain Optimistic: Analysts from Stifel, Oppenheimer, and Wolfe Research maintained positive ratings on CMPS, with Oppenheimer setting a price target of $20, indicating a potential upside of about 54%, reflecting a strong belief in the long-term market opportunity for COMP360 despite the current stock price not fully capturing its potential.
- Market Reaction Volatility: CMPS shares experienced a trading session with swings of up to 10%, ultimately closing up 1% at $12.99, indicating that investors were taking profits after the positive data release; analysts suggest this volatility may be an overreaction to good news, with expectations of a rebound in momentum.
- Retail Investor Sentiment Bullish: According to a Stocktwits poll, retail sentiment around CMPS remains in the 'bullish' zone, with 25% of approximately 750 respondents expressing confidence in the stock's prospects over the next five years, further supporting its market outlook.
See More
Compass Pathways' COMP360 Shows Strong Phase 3 Data for TRD
- Clinical Trial Results: Among patients receiving a 25 mg dose, 39% achieved a clinically meaningful reduction in depression symptoms by Week 6 and maintained these benefits through at least Week 26, significantly improving on the 25% response rate seen in the COMP005 trial, indicating COMP360's potential in treating treatment-resistant depression (TRD).
- Positive Stock Reaction: Shares of Compass Pathways jumped over 10% in pre-market trading on Tuesday, and if current levels hold after the opening bell, it would mark the biggest single-day gains in nearly two months, reflecting strong market confidence in the new therapy.
- FDA Application Progress: The company has begun a rolling New Drug Application submission to the U.S. FDA, with the final filing expected in Q4 2026, and if approved, COMP360 is anticipated to launch in the first half of 2027, further advancing its late-stage PTSD program.
- Optimistic Market Sentiment: Retail sentiment surrounding CMPS on Stocktwits remained in the 'bullish' zone, with message volumes surging 225% over a 24-hour period, as some users predict the stock could climb to $20 before the closing bell, representing a potential 35% increase.
See More
Compass Pathways Releases New Data on COMP360 for Treatment-Resistant Depression
- Clinical Trial Progress: Compass Pathways confirmed the potential of COMP360 against treatment-resistant depression in its 581-patient Phase 3 COMP006 trial, with 26-week results demonstrating rapid onset and durable clinical effects, boosting market confidence in its therapy.
- Efficacy Data Highlights: In the COMP006 trial, 39% of patients receiving two doses of 25 mg COMP360 achieved at least a 25% reduction in MADRS scores by Week 6, compared to only 25% in the COMP005 trial, indicating the clinical benefits of dose escalation.
- Safety Profile Remains Strong: The experimental therapy showed no new safety events and continued to indicate a well-tolerated safety profile, enhancing investor confidence in its future market performance.
- FDA Application Progress: Compass Pathways is conducting a rolling submission for a new drug application expected to conclude in Q4 2024, with COMP360 anticipated to launch in H1 2027, subject to FDA approval, further driving company growth.
See More
